Strain improvement of Lentzea sp. 7887 for higher yield per unit volume on hydroxylation of cyclosporine derivative FR901459

Abstract

A Gram-positive bacterium Lentzea sp. 7887 hydroxylates a cyclosporine derivative FR901459 into AS1837812 (9-hydroxide), which is an important intermediate of candidate drugs that target the hepatitis C virus. We screened a UV-induced mutant, named M-1, which showed about 1.2-fold higher conversion yields, 2-fold higher substrate concentrations (3.69 mM), and 2.5-fold higher yield per unit volume than the wild-type strain.

Lentzea tibetensis sp. nov., a novel Actinobacterium with antimicrobial activity isolated from soil of the Qinghai–Tibet Plateau

“…Average nucleotide identity (ANI) between the genomes was calculated using FastANI [38] based on blastn (ANIb). Since previous studies have shown that Lentzea strains could produce a variety of bioactive secondary metabolites [39][40][41], the genome sequence of FXJ1.1311 T was submitted to the antibiotics and Secondary Metabolite Analysis SHell (antiSMASH) version 5.0 [42] to analyse its potential to produce secondary metabolites.…”